

Sequence comparison A

SQ Sequence 649 AA; Query Match 100.0%; Score 1121; DB 23; Length 649; Best Local Similarity 100.0%; Pred. No. 7.2e-103; Matches 208; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ALPAKPNISCVYYRKNLTCTWSPGKETSQYTVKRTYAFGEKHDNCTTNSSTSENRA 60
 DB 20 ALPAKPNISCVYYRKNLTCTWSPGKETSQYTVKRTYAFGEKHDNCTTNSSTSENRA 79
 QY 61 SCSEFLPRITIPDNYTIEVEAENGDCVVKSHMTYWRLENIAKTEPPKIFRVKPVLGIRKM 120
 DB 80 SCSEFLPRITIPDNYTIEVEAENGDCVVKSHMTYWRLENIAKTEPPKIFRVKPVLGIRKM 139
 QY 121 IQIEWIKPELAPVSSDLKYLTLRFTVNSTSWMEVNFANRKKDKQNTYNTLGLQPFTEYVI 180
 DB 140 IQIEWIKPELAPVSSDLKYLTLRFTVNSTSWMEVNFANRKKDKQNTYNTLGLQPFTEYVI 199
 QY 181 ALCAVKESKFWSDWSQERKGMTEEAP 208
 DB 200 ALCAVKESKFWSDWSQERKGMTEEAP 227

RESULT 10

AAE24028 standard; Protein; 652 AA.

AAE24028
 ID AAE24028 standard; Protein; 652 AA.
 AC AAE24028;
 XX
 XX
 DT 26-MAR-2001 (first entry)
 XX
 DE Human haemopoietin receptor protein NR10.1 SEQ ID NO:2.
 XX
 KW Human; haemopoietin receptor; NR10.1; NR10.2; NR10.3; NR10;
 KW immunoregulation; haematopoietic cell regulation; transmembrane;
 KW immune disorder; haematopoietic disorder; autoimmune disease; allergy;
 KW metal allergy; pollen allergy.
 XX
 OS Homo sapiens.

WP04004514-A1.

14-DEC-2000.

01-JUN-2000; 2000WO-JP03556.
 02-JUN-1999; 99JP-0155797.
 30-JUL-1999; 99JP-0217797.
 (CHUGAI) CHUGAI RES INST MOLECULAR MEDICINE INC.

Maeda M, Yaguchi N;

WP1: 2001-061720/07.

N-PSDB; AAC92337.

Hematopoietin receptor protein NR10 for screening potential ligands for treatment of immune and hematopoietic disorders such as autoimmune diseases and allergies -

Claim 1; Fig 3-5; 127pp; Japanese.

The present sequence represents a human haemopoietin receptor protein (NR10), specifically designated NR10.1. NR10 occurs as a transmembrane protein and a soluble protein. NR10 is a haemopoietin receptor molecule which participates in immunoregulation and haematopoietic cell regulation in vivo, and is useful in searching for haematopoietic factors capable of binding to the receptor. NR10 can be used for the identification of substances for the treatment and prevention of immune and haematopoietic disorders including autoimmune diseases and allergies such as metal and pollen allergy.

Sequence 652 AA;

Query Match 100.0%; Score 1121; DB 22; Length 652; Best Local Similarity 100.0%; Pred. No. 7.3e-103; Matches 208; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ALPAKPNISCVYYRKNLTCTWSPGKETSQYTVKRTYAFGEKHDNCTTNSSTSENRA 60
 DB 33 ALPAKPNISCVYYRKNLTCTWSPGKETSQYTVKRTYAFGEKHDNCTTNSSTSENRA 92
 QY 61 SCSEFLPRITIPDNYTIEVEAENGDCVVKSHMTYWRLENIAKTEPPKIFRVKPVLGIRKM 120
 DB 93 SCSEFLPRITIPDNYTIEVEAENGDCVVKSHMTYWRLENIAKTEPPKIFRVKPVLGIRKM 152
 QY 121 IQIEWIKPELAPVSSDLKYLTLRFTVNSTSWMEVNFANRKKDKQNTYNTLGLQPFTEYVI 180
 DB 153 IQIEWIKPELAPVSSDLKYLTLRFTVNSTSWMEVNFANRKKDKQNTYNTLGLQPFTEYVI 212
 QY 181 ALCAVKESKFWSDWSQERKGMTEEAP 208
 DB 213 ALCAVKESKFWSDWSQERKGMTEEAP 240

RESULT 11

AAE24028 standard; Protein; 652 AA.

AAE24028;
 XX
 XX
 DT 23-SEP-2002 (first entry)
 XX
 DE Human HPR1 variant protein #2.
 XX
 KW Human; haematopoietin receptor; receptor; HPR1; HPR2; cell proliferation;
 KW pancytopenia; leukopenia; anaemia; thrombocytopenia; osteoporosis;
 KW neurodegenerative disorder; leukaemia; carcinoma; haematologic disorder;
 KW cancer; myelodysplastic syndrome; idiopathic thrombocytopenic purpura;
 KW ITP; sickle cell vasculocytic crisis; myelofibrosis; myeloid metaplasia;
 KW osteoclast disorder; periodontitis; acute polynuropathy; Bell's palsy;
 KW anorexia nervosa; chronic fatigue syndrome; Creutzfeldt-Jacob disease;
 KW demyelinating neuropathy; Guillain-Barre syndrome; Gulf war syndrome;
 KW vertebral disc disease; myasthenia gravis; chronic neuronal degeneration;
 KW stroke; fatigue; tumour; sarcoma; osteoporosis; obesity; infertility;
 KW ischaemic disease; variant.
 XX
 OS Homo sapiens.

WO200229060-A2.

11-APR-2002.

05-OCT-2001; 2001WO-US31634.

06-OCT-2000; 2000US-238706P.

13-OCT-2000; 2000US-240476P.

20-FEB-2001; 2001US-270282P.

(IMMV) IMMUNEX CORP.

Cosman DJ, Mosley BA, Bird TA, Dubose RF, Wiley SR;

WPI; 2002-330172/36.

Human and murine hematopoietin receptor polypeptides HPR1 and HPR2, useful for treating cell proliferation, metabolic, and reproductive hormone related conditions -

Disclosure; Page 110-112; 136pp; English.

The present invention relates to human and murine haematopoietin receptor polypeptides HPR1 and HPR2. Sequences of the invention are useful for treating cell proliferation conditions e.g., pancytopenia, leukopenia, anaemia, thrombocytopenia, neurodegenerative disorders and osteoporosis resulting from a lack of bone-forming cells. They are also useful for